Clinical Relevance of Brain Volume Measures in Multiple SclerosisNicola De Stefano, Bernd C. Kieseier, Laura Airas et al.|CNS Drugs|2014Cited by 293
The role of microglia in multiple sclerosis: implications for treatment with Bruton’s tyrosine kinase inhibitorsPatrick Vermersch, Celia Oreja‐Guevara, Laura Airas et al.|Frontiers in Immunology|2025Cited by 17
Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year inMaura Pugliatti, Thomas Berger, Hans‐Peter Hartung et al.|Frontiers in Immunology|2022Cited by 11
Generics, Biosimilars and Follow‐On Non‐Biologic Complex Drugs for Multiple Sclerosis: A Narrative Review of the Regulatory and Clinical Implications for European NeurologistsThomas Berger, Celia Oreja‐Guevara, Markus Zeitlinger et al.|European Journal of Neurology|2025Cited by 4
Increased TSPO-binding Associates with Brain Atrophy in Multiple SclerosisAbhijith Yenikekaluva, Laura Airas, Tanja Sjöros et al.|Åbo Akademi University Research Portal|2025Cited by 0